Your browser doesn't support javascript.
loading
SCO-267, a GPR40 Full Agonist, Improves Glycemic and Body Weight Control in Rat Models of Diabetes and Obesity.
Ueno, Hikaru; Ito, Ryo; Abe, Shin-Ichi; Ookawara, Mitsugi; Miyashita, Hirohisa; Ogino, Hitomi; Miyamoto, Yasufumi; Yoshihara, Tomoki; Kobayashi, Akihiro; Tsujihata, Yoshiyuki; Takeuchi, Koji; Watanabe, Masanori; Yamada, Yukio; Maekawa, Tsuyoshi; Nishigaki, Nobuhiro; Moritoh, Yusuke.
Afiliação
  • Ueno H; Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).
  • Ito R; Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).
  • Abe SI; Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).
  • Ookawara M; Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).
  • Miyashita H; Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).
  • Ogino H; Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).
  • Miyamoto Y; Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).
  • Yoshihara T; Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).
  • Kobayashi A; Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).
  • Tsujihata Y; Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).
  • Takeuchi K; Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).
  • Watanabe M; Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).
  • Yamada Y; Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).
  • Maekawa T; Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.).
  • Nishigaki N; Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.) nobuhiro.nishigaki@takeda.com.
  • Moritoh Y; Takeda Pharmaceutical Company Limited, Kanagawa, Japan (H.U., R.I., H.M., H.O., Y.Mi., T.Y., Y.T., K.T., N.N.); and SCOHIA PHARMA, Inc., Kanagawa, Japan (S.A., M.O., A.K., M.W., Y.Y., T.M., Y.Mo.) yusuke.moritoh@scohia.com.
J Pharmacol Exp Ther ; 370(2): 172-181, 2019 08.
Article em En | MEDLINE | ID: mdl-31182471
ABSTRACT
The GPR40/FFA1 receptor is a G-protein-coupled receptor expressed in the pancreatic islets and enteroendocrine cells. Here, we report the pharmacological profiles of (3S)-3-cyclopropyl-3-{2-[(1-{2-[(2,2-dimethylpropyl)(6-methylpyridin-2-yl)carbamoyl]-5-methoxyphenyl}piperidin-4-yl)methoxy]pyridin-4-yl}propanoic acid (SCO-267), a novel full agonist of GPR40. Ca2+ signaling and insulin and glucagon-like peptide-1 (GLP-1) secretion were evaluated in GPR40-expressing CHO, MIN6, and GLUTag cells. Hormone secretions and effects on fasting glucose were tested in rats. Single or repeated dosing effects were evaluated in neonatally streptozotocin-induced diabetic rats (N-STZ-1.5 rats), diet-induced obese (DIO) rats, and GPR40-knockout (Ffar1-/- ) mice. Treatment with SCO-267 activated Gq signaling in both high- and low-FFAR1-expressing CHO cells, stimulated insulin secretion in MIN6 cells, and induced GLP-1 release in GLUTag cells. When administered to normal rats, SCO-267 increased insulin, glucagon, GLP-1, glucose-dependent insulinotropic peptide, and peptide YY (PYY) secretions under nonfasting conditions. These results show the full agonistic property of SCO-267 against GPR40. Hypoglycemia was not induced in SCO-267-treated rats during the fasting condition. In diabetic N-STZ-1.5 rats, SCO-267 was highly effective in improving glucose tolerance in single and 2-week dosing studies. DIO rats treated with SCO-267 for 2 weeks showed elevated plasma GLP-1 and PYY levels, reduced food intake, and decreased body weight. In wild-type mice, SCO-267 induced GLP-1 secretion, food intake inhibition, and body weight reduction; however, these effects were abolished in Ffar1-/- mice, indicating a GPR40-dependent mechanism. In conclusion, SCO-267 stimulated islet and gut hormone secretion, improved glycemic control in diabetic rats, and decreased body weight in obese rats. These data suggest the therapeutic potential of SCO-267 for the treatment of diabetes and obesity.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Propionatos / Piridinas / Glicemia / Peso Corporal / Ciclopropanos / Receptores Acoplados a Proteínas G / Diabetes Mellitus Experimental / Obesidade Limite: Animals / Humans / Male Idioma: En Revista: J Pharmacol Exp Ther Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Piperidinas / Propionatos / Piridinas / Glicemia / Peso Corporal / Ciclopropanos / Receptores Acoplados a Proteínas G / Diabetes Mellitus Experimental / Obesidade Limite: Animals / Humans / Male Idioma: En Revista: J Pharmacol Exp Ther Ano de publicação: 2019 Tipo de documento: Article